No Data
December Starts With a Mixed Market | Live Stock
Amgen, Nike Share Losses Lead Dow's 115-Point Drop
Evercore Maintains Amgen(AMGN.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN)
Express News | Amgen : Deutsche Bank Cuts Target Price to $285 From $305
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.